SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to its recent earnings report and subsequent conference call, with community members actively debating the company's financial health and management's communication style. Discussions revolve around revenue beats versus significant losses, government funding prospects, and the long-term viability of the quantum computing sector. Bears express concern about cash burn and profitability while bulls cite strong revenue growth and potential for future success.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snapchat is trending following earnings, with community chatter focused on a reported AI partnership with Perplexity and a significant stock buyback program. While some traders are cashing out after an initial surge, others speculate about future growth and potential analyst upgrades. Discussions also involve the overall health of social media equities and their potential for increased advertising revenue.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as the community discusses the implications of its earnings report, with debates focusing on whether the results justify the current valuation and if recent growth can be sustained. A key point of discussion revolves around the CFO's upcoming retirement and its potential impact. Some traders anticipate upgrades, while others believe the stock is overbought, creating contrasting perspectives.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending as investors dissect recent news and anticipate the upcoming earnings call, focusing on updates regarding customer qualifications, particularly with Honor, and potential PO announcements. The community is weighing the significance of potential acquisitions and manufacturing expansions in Malaysia and Korea, while also considering the broader implications for the battery sector. Discussions revolve around whether Enovix can meet its targets and deliver on long-awaited commercial traction.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo's stock is trending amidst discussions about its earnings report, with some investors believing the dip presents a buying opportunity and predicting a quick rebound. Community debates center around the impact of AI on Duolingo's business model, with some seeing AI as a threat and others emphasizing Duolingo's unique AI-driven approach and strong user base. Despite mixed sentiment, some analysts maintain high price targets, contributing to the ongoing volatility.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending due to its announcement of new AI chips aimed at the data center market, sparking community discussion about its potential to compete with NVIDIA and AMD. Community members are debating the long-term impact of this diversification and whether the initial surge in stock price is justified, considering the timeline for product availability and disclosed partnerships. Some investors express skepticism, citing concerns about lower-end chip specifications and limited revenue potential compared to the market cap increase.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors discuss its "Token Factory" AI inference platform and potential competition with major cloud providers. Community members are highlighting the company's diverse client base and upcoming data center opening, speculating on potential catalysts for further stock movement. Some are drawing parallels to Palantir's early growth, while others focus on Nebius's potential to disrupt the AI cloud landscape.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending following the release of earnings, with key highlights including revenue and EPS beats, as well as raised FY25 sales outlook; the community is weighing in on growth, margin compression, and long-term potential. Bullish sentiment is building with some anticipating a continued run, while others remain cautious, citing valuation and broader economic concerns. Discussions also involve comparisons to Starbucks and the competitive landscape within the beverage sector.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma ($FIG) is trending as investors discuss its recent earnings report, which beat expectations and raised revenue guidance; the community is also buzzing about a potential short squeeze. Bullish sentiment revolves around Figma's strong position in the design software space and AI integrations, while some express concerns over valuation and profitability.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Root Inc. is trending as investors digest recent earnings and debate the company's path to profitability. Community discussions center on revenue growth, policy increases, and the impact of one-time expenses, with some expressing concerns about operating costs. Sympathy moves with sector peer Lemonade are also fueling trading action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +5.26% and -70.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics, Inc. (VRDN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Viridian Therapeutics (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Retail chatter spiked around Invivyd on Monday after the company said its monoclonal antibodies pemivibart and VYD2311 continued to neutralize the emerging XFG variant of COVID-19 in laboratory tests.The company reported that both antibodies remained effective against XFG, which U.S. Centers for Disease Control and Prevention data and wastewater surveillance suggest is driving a rising wave of infections in the U.S.&nbsp;Similar results were shown against other circulating variants, including NB.1.8.1, LF.7.9 and LP.8.1. Invivyd said it identified no resistant strains.The data will be submitted to the U.S. Food and Drug Administration (FDA) for planned inclusion in the fact sheet for pemivibart, which is currently authorized under emergency use for pre-exposure prevention of COVID-19 in certain immunocompromised patients.The update follows news last week that Invivyd reached alignment with the FDA on a streamlined regulatory pathway for VYD2311.&nbsp;In a recent Type C meeting, the agency advised that a single Phase 2/3 randomized, placebo-controlled trial with a relatively modest number of symptomatic COVID-19 cases could support a biologics license application.&nbsp;Invivyd said it plans to test two doses of VYD2311 and has clinical supply on hand.Infections are growing or likely growing in 34 states, with wastewater data showing high or very high viral levels in 12 states, the company said, citing CDC forecasts.&nbsp;Invivyd said the structural target of its antibodies has remained stable across major variants since Omicron BA.2, supporting continued neutralization activity.On Stocktwits, retail sentiment for Invivyd was ‘bullish’ amid a 175% surge in 24-hour message volume.One user noted they had seen Invivyd fall to $0.48 before quickly rebounding above $1, adding that good timing was the only way to make money with the stock.&nbsp;<stembedurl>https://stocktwits.com/Jack696/message/625670790</stembedurl>Another user said they had added to their position at $0.61.<stembedurl>https://stocktwits.com/alexx013/message/625643913</stembedurl><a href="https://stocktwits.com/symbol/IVVD">Invivyd’s stock</a> has risen 31% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Invivyd’s (IVVD) stock has risen 31% so far in 2025. (Photo credit: Getty Images)

Retail Chatter Surges Around Invivyd After Data Show Pemgarda Neutralizes XFG COVID-19 Variant

The company also recently aligned with the FDA on a streamlined path to potential approval for its next-generation antibody VYD2311.

Equity

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -200.00% and -23.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of +17.95% and +57.17%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of +33.33% and +177.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Retail buzz around Invivyd Inc. spiked on Monday after it revealed its launch of a discovery program to create a measles-specific monoclonal antibody.&nbsp;Healthcare providers managing measles patients and outbreak situations contacted Invivyd to explore access to its prospective medicine since no approved treatments or post-exposure prophylaxis options exist for measles.Invivyd shares surged 29.7% on Monday to close at $0.84.Currently, clinicians lack numerous treatment options for managing measles cases.&nbsp;Children who have contracted measles receive high-dose Vitamin A to aid their recovery process, especially when their bodies lack Vitamin A.&nbsp;While high-dose Vitamin A therapy helps treat measles in children who have a deficiency of the vitamin, it shows potential liver toxicity and remains underutilized.&nbsp;Human donor-derived pooled plasma immune globulin (IVIG) is a mix of different antibodies from several donors that hasn't been officially approved, and its inconsistent makeup makes it less reliable for widespread use.Measles vaccines stand as the best protective measure available, yet their effectiveness diminishes because some populations fail to access or refuse them, leaving unprotected gaps after exposure to the virus.&nbsp;The latest research indicates that diseases like measles, which were previously under control, could reemerge and lead to serious outcomes such as pneumonia, encephalitis,&nbsp; and long-lasting immunological consequences.The monoclonal antibody discovery program of Invivyd would grow its portfolio, which presently contains next-generation treatments for COVID-19, respiratory syncytial virus (RSV), and influenza.&nbsp;Retail sentiment around Invivyd turned ‘extremely bullish’, with a 4,800% spike in 24-hour message volume.&nbsp;Some users expressed confidence that the stock could reach multiple dollars, while others pointed to monoclonal antibodies as the “future of medicine.”<stembedurl>https://stocktwits.com/trader2sde/message/614373951</stembedurl><stembedurl>https://stocktwits.com/TheFnFortune/message/614327973</stembedurl>The stock has risen 74.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’

Invivyd unveiled a discovery program for a measles-targeted monoclonal antibody, responding to provider demand amid a lack of approved treatments or post-exposure options. 

These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.

IVVD
Invivyd Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IVVD News

IVVDInvivyd Inc